Discover an informative webinar focusing on the advancements in glucagon-like peptide 1 (GLP-1) receptor agonists and their transformative role in diabetes and obesity management.

Diabetes and obesity management is undergoing a remarkable transformation with the advent of GLP-1 receptor agonists. These agents not only promise significant advances in controlling blood glucose and reducing weight but also herald a new era in precision medicine.

In this webinar, the expert speaker will examine the multi-decade journey of GLP-1 receptor agonists from initial discovery to their current status as a cornerstone in the management of metabolic disorders. They will discuss the mechanism of action of these drugs, their clinical benefits and the innovative strides being made to enhance their efficacy and patient compliance through novel delivery systems.

They will also highlight the evolution of GLP-1 receptor agonists, showcasing improvements in drug efficacy and delivery that have expanded their indications from diabetes to weight management and beyond. The discussion will include a review of the latest advancements such as the introduction of once-weekly injectable forms and oral preparations that promise to improve patient adherence and outcomes.

Furthermore, the webinar will explore the critical role of these drugs in the broader context of healthcare, including their potential to reduce major cardiovascular events and support sustainable healthcare practices. As we look towards the future, the webinar will focus on the integration of precision medicine principles in the development and application of GLP-1 receptor agonists.

Read Less...

The speaker will also argue for a targeted approach, where genetic and pharmacogenomic data are utilized to tailor treatments to individual patient profiles, thereby optimizing therapeutic outcomes and minimizing adverse effects. The webinar will conclude with a discussion on the ethical, economic and clinical implications of widespread GLP-1 use and the strategies to make these powerful therapies accessible while ensuring they deliver on their promise of transforming patient care in diabetes and obesity management.

Register for this webinar today to gain insights into the revolutionary impact of GLP-1 receptor agonists on diabetes and obesity management.

Keywords:

Speaker

Dr. Yuri Fesko, MD, Chief Medical Officer, Quest Diagnostics

Located in the New York City Metropolitan Area, Dr. Yuri Fesko is a board-certified Medical Oncologist and the Chief Medical Officer at Quest Diagnostics. With over two decades of experience in clinical practice and medical leadership, Dr. Fesko leads the company’s medical affairs, clinical development and strategic medical initiatives — particularly in oncology diagnostics and precision medicine.

He has pioneered innovative diagnostic solutions, including the development of the next-generation sequencing panel and decentralized clinical trials, enhancing patient care and healthcare affordability. An active speaker and published author, Dr. Fesko’s work continues to influence global healthcare advancements.

Message Presenter

Who Should Attend?

This webinar is designed for healthcare professionals, industry experts and pharmaceutical partners who are interested in the latest advancements in diabetes and obesity management.

What You Will Learn

Attendees will learn about:

The transformative role of GLP-1 receptor agonists in treating diabetes and obesity
Advancements in drug delivery systems that improve patient adherence and outcomes
How precision medicine tailors GLP-1 therapies to enhance treatment effectiveness and safety
The economic and ethical challenges of broad GLP-1 use and strategies for sustainable healthcare integration

Xtalks Partner

Quest Diagnostics

When you choose Quest Diagnostics as your partner in BioPharma Services, you get more than lab testing. Access the reach, expertise, and renowned quality of Quest Diagnostics for every milestone of your program—from R&D consulting through clinical trials, companion diagnostic development, commercialization, and post-launch surveillance. Together we have the power to deliver better outcomes.